| Document |
Document Title |
|
WO/2019/210879A1 |
The present invention relates to a bicyclic nucleocapsid inhibitor and use thereof as a drug for treating hepatitis B. Specifically, disclosed is a compound which can be used as an HBV inhibitor and has a structure represented by chemica...
|
|
WO/2019/212937A1 |
The present invention relates to pyridazinones and related compounds of Formula I which are inhibitors of PARP7 and are useful in the treatment of cancer.
|
|
WO/2019/199972A1 |
Described herein are splice modifying compounds affecting splicing of mRNA, such as pre-mRNA, expressed from the FOXM1 gene, compositions comprising thereof, and methods using the same.
|
|
WO/2019/189555A1 |
Provided is a compound that can have a CDK12-inhibiting effect and that is expected to be useful as a preventive or therapeutic drug for cancer and the like. The compound or salt thereof is represented by formula (I) (where each symbol i...
|
|
WO/2019/143508A1 |
Efficient methods are provided for large scale production of ethyl cocaine-free cocaine hydrochloride. Compositions and methods comprising administration of cocaine hydrochloride are provided.
|
|
WO/2019/141096A1 |
Provided is a substituted urea compound, and a preparation method and use thereof. More particularly, the invention relates to a substituted urea compound or a pharmaceutically acceptable salt, a stereoisomer, a polymorphic substance, a ...
|
|
WO/2019/126253A1 |
Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmace...
|
|
WO/2019/110521A1 |
The present invention relates to fluorophenyl substituted muscarinic receptor ligands with selectivity for M3 over M2 and to the use of these compounds in the treatment of various diseases such as asthma, chronic obstructive pulmonary di...
|
|
WO/2019/104011A1 |
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the en...
|
|
WO/2019/099307A1 |
The present technology is directed to compounds, compositions, and methods related to inhibition of ASK1. In particular, the present compounds (e.g., compounds of Formula I as defined herein) and compositions may be used to treat ASK1-me...
|
|
WO/2019/084383A1 |
The invention provides a compound of formula (I): (Formula (I)) or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a cryst...
|
|
WO/2019/079626A1 |
Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by...
|
|
WO/2019/040105A2 |
The present disclosure relates to compounds according to Formula (I), treating diseases.
|
|
WO/2019/038656A1 |
The present invention relates to parenteral formulations comprising Palonosetron, NK1 receptor antagonist and a corticosteroid. The present invention also relates to process of preparing such formulations.
|
|
WO/2019/040106A2 |
The present disclosure relates to compounds according to Formulae disclosed herein, useful for treating diseases.
|
|
WO/2019/040107A1 |
The present disclosure relates to compounds according to Formula (I), useful for treating diseases.
|
|
WO/2019/036384A1 |
The present disclosure provides tricyclic compounds of formula (I) that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as can...
|
|
WO/2019/031618A1 |
The present invention provides a compound represented by formula [I], the compound exhibiting the effect of inhibiting an enzyme that produces 20-HETE, or a pharmaceutically acceptable salt thereof. (In formula [I], the structure represe...
|
|
WO/2019/021140A1 |
The present technology relates to molecules that stimulate the immune system for use in treating drug abuse and addiction, and to the methods of synthesis thereof. Said molecules comprise a calixarene chemical structure, preferably calix...
|
|
WO/2019/008025A1 |
The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylure...
|
|
WO/2018/235813A1 |
A compound represented by the formula, which has an RORĪ³t inhibiting effect and is useful as a prophylactic or therapeutic agent for autoimmune diseases, allergic diseases, etc., or a salt thereof.
|
|
WO/2018/168643A1 |
Provided is a method for producing [123I] ioflupane in a large quantity without deteriorating the quality thereof. The method is a method for producing radioactive-iodine-labeled ioflupane, comprising the steps of (a) reacting a labeling...
|
|
WO/2018/154596A1 |
Provided herein is a process for synthesis of tiotropium bromide wherein the coupling of scopine with 2, 2-dithienyl glycolate is achieved by a two step process under mild conditions.
|
|
WO/2018/151678A1 |
The present invention relates to heterocyclic compounds having the general Formula (I) wherein W1, W2, W3, W4, W7, W8, R1, R2, R3, R4, X2, X3, X4, Z1, Z2, Z3, Q, n and m are as defined herein, or a pharmaceutically acceptable salt thereo...
|
|
WO/2018/145216A1 |
An herbal pharmaceutical compositions of California poppy and methods for the treatment of sleep disorders and dream-related disorders is disclosed. The formulation may be in the form of capsules, tablets, caplets or other oral dosage fo...
|
|
WO/2018/124001A1 |
The present invention pertains to novel, exceptional low-molecular compounds that specifically antagonize the BMP signaling pathway, and because these compounds can be used to modulate cell growth, differentiation, proliferation, and apo...
|
|
WO/2018/115591A1 |
Compounds of formula (I) wherein R1, R2,R3,R4,R5,R23,R24,L, A and Bare as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1(...
|
|
WO/2018/084817A2 |
The present invention relates to a new crystalline form of an active agent, the preparation processes of said crystalline form, the pharmaceutical compounds containing said crystalline form and the use of said compounds in the treatment ...
|
|
WO/2018/083101A1 |
The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for p...
|
|
WO/2018/083103A1 |
The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for p...
|
|
WO/2018/055642A1 |
Provided herein is a process for synthesis of tiotropium bromide and a process for synthesis of scopine starting from a dimethyl tartarate compound. The synthetic sequence comprises a double Mannich reaction (Robinson-Schopf reaction).
|
|
WO/2018/057596A1 |
A nasal spray composition and method for treating convulsive seizures, including epileptic seizures, and also autism behavioral events. In embodiments, the nasal spray composition contains delta-9-tetrahydrocannabinol and, optionally, te...
|
|
WO/2018/031434A1 |
The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
|
|
WO/2018/009017A1 |
The present invention relates to 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical compositions containing the same, wherein the 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composit...
|
|
WO/2017/216159A1 |
The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.
|
|
WO/2017/212425A1 |
The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, z2, z4, z5, and z6 are as define...
|
|
WO/2017/201468A1 |
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or condit...
|
|
WO/2017/197177A1 |
In various embodiments, compositions and methods are provided for treatment and/or prevention of amyloidogenic diseases. In certain embodiments, the methods entail administering an effective amount of compound C41 to a subject in need th...
|
|
WO/2017/193951A1 |
Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.
|
|
WO/2017/189822A1 |
The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compos...
|
|
WO/2017/179976A1 |
The invention relates to improved means and methods for N- dealkylation of alkylated amines. Provided is a method for the catalytic N- dealkylation of an N-alkylated amine substrate, comprising incubating said amine substrate in a suitab...
|
|
WO/2017/165822A1 |
A compound, or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, according to formula (III) or according to Table A, a pharmaceutical composition comprising said compound and at least one pharmaceutically acceptable add...
|
|
WO/2017/148519A1 |
The invention relates to new heteroaryl derivatives of the formula wherein X 1 is selected from the group consisting of: N and CH; X 2 is selected from the group consisting of: N and CF; (whith the proviso that at least one of X1 and X2 ...
|
|
WO/2017/144978A1 |
Proposed are a salt of tesofensine with optically-active acetylamino acids, and a method for producing same. The invention also relates to pharmaceutical compositions including a salt of tesofensine with optically-active acylamino acids ...
|
|
WO/2017/141927A1 |
The present invention provides a compound represented by formula [I'], which has the effect of inhibiting an enzyme which produces 20-HETE, or a pharmaceutically acceptable salt thereof. (In formula [I']: the structure represented by for...
|
|
WO/2017/138896A1 |
The present invention relates to a new crystalline form of an active agent, the processes for preparing this crystalline form, the pharmaceutical compositions comprising this crystalline form and the use of these compositions in the trea...
|
|
WO/2017/123542A1 |
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: Formula (I) wherein R1 and ...
|
|
WO/2017/102091A1 |
The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, ...
|
|
WO/2017/090756A1 |
Provided is a compound represented by general formula (I) or a salt thereof. Also provided is an LSD1 inhibitor that contains this compound or a salt thereof as an active ingredient. Also provided is a pharmaceutical composition that con...
|
|
WO/2017/069226A1 |
A compound represented by general formula [I] (in the formula, X represents N or the like, Y represents CH or the like, RA represents an optionally substituted cycloalkyl group or the like, R1 represents an alkyl group or the like, R2 re...
|
